By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after ...

Novo Nordisk’s new weight-loss drug helped patients lose even more weight on average than its current Wegovy blockbuster ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

The Phase 3 study showed that type 2 diabetes patients taking the highest dose of daily orforglipron lost nearly 8% of their ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Hims wasn’t stepping back enough from its practice of mass marketing compounded versions of the weight-loss medicine, said ...

Novo Nordisk is ending a deal with telehealth company Hims & Hers, saying Monday that Hims has been engaging in “illegal mass ...

Lower blood sugar and increased fat burning – without negatively affecting appetite or muscle mass. These are some of the ...

Obesity caused by a high-fat Western diet damages the pancreas, affecting insulin production and blood sugar control even ...